大数跨境
0
0

Medicilon | Featured Sponsor for ACCESS ASIA BD Forum @ JPM 2026

Medicilon | Featured Sponsor for ACCESS ASIA BD Forum @ JPM 2026 雅法全球生命科学
2025-11-06
17

January 11, 2026 | InterContinental San Francisco




In a world where biotech innovation thrives on collaboration, we're proud to announce Medicilon as the Featured Sponsor for the ACCESS ASIA BD Forum @ JPM 2026.


As a global leader in integrated preclinical research services, Medicilon has long been the bridge between discovery and IND, supporting innovators from concept to clinical readiness. Their tagline — “Concept to IND, Tailored to Your Needs” — captures their mission to accelerate drug discovery through seamless, world-class scientific partnerships.



About Medicilon


From its inception in 2004, Shanghai Medicilon Inc. has been committed to providing comprehensive R&D services to pharmaceutical companies, research institutions, and any organizations working in the preclinical space. Medicilon has built an integrated one-stop R&D platform covering drug discovery, CMC and preclinical studies, and has established service platforms in cutting-edge fields such as ADC, nucleic acids, peptides, CGT, PROTAC, and antibodies. Medicilon has established a quality system in compliance with international standards and has obtained GLP certifications from China’s NMPA, the US FDA, the EU OECD, and Japan’s PMDA, as well as AAALAC accreditation. Currently, Medicilon has nearly 80,000 square meters of R&D laboratories.


Medicilon Boston, part of Medicilon's global dual-site operations (Boston, USA and Shanghai, China), offers non-GLP validated assay development with seamless workflow transfer to GLP execution in Shanghai, ensuring continuity from early discovery through IND-enabling studies. Medicilon Boston provides local accessibility with global expertise.


By the end of June 2025, Medicilon has provided drug development services to over 2,000 clients worldwide, and has been involved in the research and development of 588 new drugs and generic drug projects that have been approved for clinical trials with IND applications.


Their integrated model empowers biotech firms — especially early-stage innovators — to achieve IND milestones globally, aligning perfectly with ACCESS ASIA’s mission to connect Asian innovation with global opportunity.




Shared Vision: Collaboration Beyond Borders


ACCESS ASIA BD Forum @ JPM 2026 brings together Asia’s leading biotech companies, global pharma executives, and VC/PE investors for a full day of keynotes, corporate presentations, and 1-on-1 partnering at the InterContinental San Francisco.


Medicilon’s sponsorship underscores the importance of partnership — not only between science and business but between regions and ecosystems shaping the future of healthcare.





A Message of Partnership


“Medicilon’s support highlights the growing strength of Asia’s biotech sector and its global impact. Together, we’re building a platform where innovation meets collaboration — and ideas turn into breakthroughs.”



Join Us in San Francisco


January 11, 2026 | InterContinental San Francisco

🌐 Scan QR code to register


Be part of the conversations driving the next decade of global biotech growth.





💼 Interested in Sponsorship or Partnership Opportunities?


ACCESS ASIA BD Forum offers bespoke collaboration packages for industry leaders, service providers, and investors seeking visibility and engagement at one of JPM Week’s most anticipated Asia-focused biotech events.

📩 For inquiries, please contact:

📧 wxiang@yafocapital.com





UPCOMING EVENT:



The ACCESS ASIA BD Forum @ JPM 2026, hosted by YAFO Capital, is a premier cross-border partnering platform taking place on January 11, 2026, at the InterContinental San Francisco, alongside the J.P. Morgan Healthcare Conference.


Now in its sixth consecutive year, the Forum brings together global pharma, biotech, and investors for a full day of corporate presentations, keynote sessions, panel discussions, NewCo Innovation discussions, and 1-on-1 partnering meetings.


It serves as a gateway for Asian biotech innovators to connect with international partners and investors, fostering meaningful collaborations, licensing opportunities, and strategic dialogue across borders.


👉 Please click the link below to learn more:

🔗 https://biotochina.org/


Please keep checking back for more exciting speaker and session additions on our agenda:

https://biotochina.org/agenda/

【声明】内容源于网络
0
0
雅法全球生命科学
1234
内容 489
粉丝 0
雅法全球生命科学 1234
总阅读971
粉丝0
内容489